Hyseq Pharmaceuticals Inc.

Completing an initial public offering ought to be a big step in company development. It is a departure from a cosseted, insulated environment of unique technical approaches and regulatory progress and

Biotech dealmaking in the fall of 2002 was a study in crisis management. As cash-starved biotechs scrambled to avoid liquidation, they signed deals that kept them alive but hardly offered much hope fo

The merger of Cambridge Antibody and Oxford GlycoSciences won't, in the short term, solve many of the problems that both share—namely, a lack of products, scant clinical development capabilities and a

A $100 million start-up is betting that its technology for measuring millions of SNPs will create the predictive patterns that pharmacogenomics has as yet failed to deliver. t's the rare start-up that